RxDoctor Payments Data

Anthony Russo, MD

Internal Medicine · Youngstown, OHNPI 1366890410

Payments from drug & device makers

$8,459in general payments, 2019–2025

Across 536 payments — averaging $15.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$834
  • AstraZeneca$732
  • Lilly USA, LLC$647
  • Pfizer$625
  • Astellas Pharma US Inc$446
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$8,23397%
  • Education$2263%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,459 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$94,158
Medicare patients
296
Services billed
944

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban200$218,126
OzempicSemaglutide81$134,517
MounjaroTirzepatide35$54,994
JardianceEmpagliflozin46$52,018
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$46,490
Breztri AerosphereBudesonide/Glycopyr/Formoterol64$42,207
EntrestoSacubitril/Valsartan44$37,769
JanuviaSitagliptin Phosphate23$34,649
XareltoRivaroxaban38$28,565
MyrbetriqMirabegron40$28,239
FarxigaDapagliflozin Propanediol12$9,210
VascepaIcosapent Ethyl15$8,293
Repatha SureclickEvolocumab13$7,422
Lantus SolostarInsulin Glargine,hum.Rec.Anlog46$6,635
SynthroidLevothyroxine Sodium68$5,554

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$625$218,126200 claims
Novo NordiskOzempic$834$134,51781 claims
Lilly USA, LLCMounjaro$647$54,99435 claims
Boehringer IngelheimJardiance$345$52,01846 claims
AstraZenecaBreztri Aerosphere, Farxiga$732$51,41876 claims
GSKTrelegy Ellipta$225$46,49049 claims
NovartisEntresto$14$37,76944 claims
MerckJanuvia$371$34,64923 claims
Johnson & JohnsonXarelto$147$28,56538 claims
Astellas Pharma US IncMyrbetriq$446$28,23940 claims
AbbVieSynthroid$1,545$5,55468 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Youngstown

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →